Ray Dalio's KRYS Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 10,015 shares of Krystal Biotech, Inc. (KRYS) worth $2.47 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in KRYS, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 292 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Krystal Biotech (KRYS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Krystal Biotech (KRYS) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +292 | Add 3.00% | 10,015 | $246.54 |
| Q3 2025 | +9,723 | New Buy | 9,723 | $176.53 |
Ray Dalio's Krystal Biotech Investment FAQs
Ray Dalio first purchased Krystal Biotech, Inc. (KRYS) in Q3 2025, acquiring 9,723 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Krystal Biotech, Inc. (KRYS) for 2 quarters since Q3 2025.
Ray Dalio's largest addition to Krystal Biotech, Inc. (KRYS) was in Q3 2025, adding 9,723 shares worth $1.72 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 10,015 shares of Krystal Biotech, Inc. (KRYS), valued at approximately $2.47 M.
As of the Q4 2025 filing, Krystal Biotech, Inc. (KRYS) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Krystal Biotech, Inc. (KRYS) was 10,015 shares, as reported at the end of Q4 2025.